How May GIP Enhance the Therapeutic Efficacy of GLP-1?

Adipose Tissue, White / drug effects Diabetes Mellitus, Type 2 / drug therapy Gastric Inhibitory Polypeptide / pharmacology Glucagon-Like Peptide 1 / pharmacology Glucagon-Like Peptide-1 Receptor / agonists Humans Hypoglycemic Agents / pharmacology Receptors, Gastrointestinal Hormone / agonists
LY3298176 NNC00902746 glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide tirzepatide type 2 diabetes mellitus

Journal

Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516

Informations de publication

Date de publication:
06 2020
Historique:
received: 08 11 2019
revised: 30 01 2020
accepted: 06 02 2020
entrez: 13 5 2020
pubmed: 13 5 2020
medline: 4 8 2021
Statut: ppublish

Résumé

Glucagon-like peptide-1 (GLP-1) receptor agonists improve glucose homeostasis, reduce bodyweight, and over time benefit cardiovascular health in type 2 diabetes mellitus (T2DM). However, dose-related gastrointestinal effects limit efficacy, and therefore agents possessing GLP-1 pharmacology that can also target alternative pathways may expand the therapeutic index. One approach is to engineer GLP-1 activity into the sequence of glucose-dependent insulinotropic polypeptide (GIP). Although the therapeutic implications of the lipogenic actions of GIP are debated, its ability to improve lipid and glucose metabolism is especially evident when paired with the anorexigenic mechanism of GLP-1. We review the complexity of GIP in regulating adipose tissue function and energy balance in the context of recent findings in T2DM showing that dual GIP/GLP-1 receptor agonist therapy produces profound weight loss, glycemic control, and lipid lowering.

Identifiants

DOI: 10.1016/j.tem.2020.02.006 PMID: 32396843
pubmed: 32396843
pii: S1043-2760(20)30048-5
doi: 10.1016/j.tem.2020.02.006
pii:
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Receptors, Gastrointestinal Hormone 0
Gastric Inhibitory Polypeptide 59392-49-3
Glucagon-Like Peptide 1 89750-14-1
gastric inhibitory polypeptide receptor D6H00MV7K8

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

410-421

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ricardo J Samms (RJ)

Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Matthew P Coghlan (MP)

Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Kyle W Sloop (KW)

Diabetes and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: sloop_kyle_w@lilly.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tissus › Tissu conjonctif › Tissu adipeux › Tissu adipeux blanc › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Neuropeptides › Peptide gastrointestinal › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Hormones gastrointestinales › Peptides glucagon-like › Glucagon-like peptide 1 › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › How May GIP Enhance the Therapeutic Efficacy of GLP-1?
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › How May GIP Enhance the Therapeutic Efficacy of GLP-1?